-
The Tawnsaura Group LLC v. GNC Corporation et al DC
- 2:13-cv-04474
- C.D. Cal.
- Judge: S. James Otero
+1
- Filed: 06/20/2013
- Closed: 07/30/2014
- Latest Docket Entry: 09/10/2014
- PACER
- Docket updated daily
1
Plaintiff
3
Defendants
6
Accused
Products
2
Patents-in-Suit
406
Days in
Litigation
-
The Tawnsaura Group LLC v. GNC Corporation et al DC
- 2:13-cv-04474
- C.D. Cal.
- Judge: S. James Otero
+1
- Filed: 06/20/2013
- Closed: 07/30/2014
- Latest Docket Entry: 09/10/2014
- PACER
- Docket updated daily
Cause of Action
Willful Patent Infringement
Market Sector
Biotech and Pharma
Referred Judge
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method of improving the health of a subject to increase the plasma concentration of arginine in the subject to a level from a low or normal fasting concentration to a level which is up to three times an average overnight fasting arginine level
view more
|
Invalid (102)
Entry 18 |
| 2 |
The method according to claim 1, wherein the subject is in normal or good health.
|
Invalid (102)
Entry 18 |
| 15 |
The condition according to claim 1, wherein the subject is in a condition of increased or continuing brain or neural activities.
|
Invalid (102)
Entry 18 |
| 16 |
The condition according to claim 1, wherein the subject has much increased or continuing muscular activities.
|
Invalid (102)
Entry 18 |
| 18 |
The method of claim 1, wherein the oral L-citrulline is used in humans in acute dosage range from about 2.5 to 25 grams per day, in 2 or more divided doses, or in chronic dosage range from about 1.8 grams to about 15 grams per day, in 2 or more
view more
|
Invalid (102)
Entry 18 |
| 19 |
The method of claim 1, wherein the supplementation with L-citrulline is in capsule, tablet, or liquid form either as sole active ingredient or with L-ascorbic acid as a second active co-ingredient.
|
Invalid (102)
Entry 18 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method of improving the health of a subject to increase the plasma level of arginine in the subject to a level from a low or normal fasting level to a level which is up to three times an average overnight fasting level, comprising orally
view more
|
Invalid (103)
Entry 18 |
| 2 |
The method according to claim 1, wherein the subject is in good health.
|
Invalid (103)
Entry 18 |
| 20 |
The method according to claim 1, wherein the subject is in a condition of increased or continuing brain or neural activities.
|
Invalid (103)
Entry 18 |
| 21 |
The method according to claim 1, wherein the subject is in a condition of increased or continuing muscular activities.
|
Invalid (103)
Entry 18 |
| 26 |
The method according to claim 1, wherein citrulline is administered in a dosage range of from about 1.7 to about 20 grams per day.
|
Invalid (103)
Entry 18 |
| 27 |
The method according to claim 26, wherein the citrulline is administered at least twice daily.
|
Invalid (103)
Entry 18 |
| 28 |
The method according to claim 1, wherein the substance is administered in a form selected from the group consisting of: capsule, tablet and liquid.
|
Invalid (103)
Entry 18 |
| 29 |
The method according to claim 1, wherein the substance is the sole active ingredient administered.
|
Invalid (103)
Entry 18 |
